# Bifidobacterium adolescentis LMG 10502

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-adolescentis-lmg-10502
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bifidobacterium adolescentis LMG 10502, B. adolescentis LMG 10502, Bifidobacterium adolescentis strain LMG 10502, B. adolescentis strain LMG 10502, LMG 10502, Bifidobacterium adolescentis (LMG 10502)

## Overview

Bifidobacterium adolescentis LMG 10502 is a specific [probiotic](/ingredients/condition/gut-health) strain that strengthens the intestinal epithelial barrier and modulates immune responses primarily through induction of the [anti-inflammatory](/ingredients/condition/inflammation) cytokine interleukin-10 (IL-10). Its primary mechanisms involve enhancing tight junction integrity and shifting dendritic cell cytokine output toward tolerogenic profiles.

## Health Benefits

• Enhances intestinal barrier function by increasing trans-epithelial electrical resistance >120% in laboratory models (preliminary evidence)
• Promotes [anti-inflammatory](/ingredients/condition/inflammation) responses by inducing IL-10 secretion >200 pg/ml and favorable IL-10:IL-12 ratios in human immune cells (in vitro evidence)
• Supports [neurotransmitter](/ingredients/condition/cognitive) balance by modulating GABA, glutamate, and glutamine levels in animal models (preliminary evidence)
• Demonstrates high gastrointestinal survival with >10^5 CFU/g feces viability after oral administration (animal evidence)
• Produces beneficial short-chain fatty acids including acetate and lactate in a 3:2 ratio through resistant starch fermentation (in vitro evidence)

## Mechanism of Action

B. adolescentis LMG 10502 reinforces intestinal epithelial integrity by upregulating tight junction proteins, measurably increasing trans-epithelial electrical resistance (TEER) by over 120% in Caco-2 cell models. Immunologically, the strain interacts with pattern recognition receptors on dendritic cells and macrophages, driving preferential secretion of IL-10 above 200 pg/ml while suppressing pro-[inflammatory](/ingredients/condition/inflammation) IL-12, resulting in a high IL-10:IL-12 ratio indicative of a tolerogenic immune environment. This cytokine polarization likely involves Toll-like receptor signaling and downstream activation of STAT3 pathways that promote regulatory [T-cell](/ingredients/condition/immune-support) differentiation.

## Clinical Summary

Current evidence for B. adolescentis LMG 10502 is largely derived from in vitro studies using intestinal epithelial cell lines (Caco-2) and ex vivo human peripheral blood mononuclear cell (PBMC) assays, with no large-scale randomized controlled trials published specifically for this strain at the time of writing. In vitro barrier function data demonstrate a statistically significant TEER increase exceeding 120% versus control conditions, and PBMC experiments document IL-10 secretion surpassing 200 pg/ml alongside favorable IL-10:IL-12 ratios. These findings are mechanistically promising but should be interpreted cautiously, as in vitro outcomes do not always translate to equivalent clinical effects in human populations. Independent human trials with defined dosing regimens, endpoints, and adequate sample sizes are needed before robust efficacy claims can be made.

## Nutritional Profile

Bifidobacterium adolescentis LMG 10502 is a live bacterial ingredient; its nutritional contribution is primarily functional rather than macronutrient-based. As a gram-positive anaerobic bacterium, its biomass composition per typical dose (1–10 billion CFU) contributes negligible caloric value (<1 kcal per serving). Protein content of bacterial cell mass is approximately 50–60% of dry cell weight, predominantly structural and enzymatic proteins including cell wall-associated peptidoglycans and surface-layer proteins (S-layer proteins) that interact with host immune receptors. Carbohydrate content constitutes roughly 10–20% of dry cell weight, primarily as exopolysaccharides (EPS) and cell wall teichoic acids, which contribute to mucosal adhesion and [immunomodulat](/ingredients/condition/immune-support)ion. Lipid content is approximately 10–15% of dry cell weight, composed largely of membrane fatty acids including vaccenic acid (C18:1 trans-11) and branched-chain fatty acids with no significant dietary lipid contribution. Key bioactive compounds include: short-chain fatty acid (SCFA) precursor activity — this strain ferments fructooligosaccharides (FOS) and inulin to produce acetate (primary end product, ~60–80% of SCFA output) and lactate; GABA-modulating metabolic byproducts detected in animal model gut tissue at measurable concentrations affecting glutamate/glutamine cycling; surface-bound lipoteichoic acids and peptidoglycans acting as pattern recognition ligands driving IL-10 induction. B-vitamin synthesis capacity is documented for the Bifidobacterium genus broadly, including folate (B9) and riboflavin (B2), though strain-specific quantification for LMG 10502 is not yet published in peer-reviewed literature. Bioavailability note: nutritional compounds from bacterial biomass are largely non-bioavailable to the host in the conventional sense; functional effects are mediated through metabolite secretion, host receptor signaling, and [microbiome](/ingredients/condition/gut-health) modulation rather than direct nutrient absorption.

## Dosage & Preparation

No clinically studied human dosage ranges are available for Bifidobacterium adolescentis LMG 10502. Based on rat models achieving >10^5 CFU/g feces survival, typical administration would likely be in the 10^8-10^9 CFU range common for bifidobacteria, though specific forms and standardization are not established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bifidobacterium species, including B. adolescentis strains, have a well-established safety record in healthy adults and are generally recognized as safe (GRAS) by regulatory bodies, with transient bloating or mild gastrointestinal discomfort being the most commonly reported side effects during initial supplementation. Immunocompromised individuals, those with severe underlying gastrointestinal disease, or patients with central venous catheters should exercise caution and consult a healthcare provider before use, as rare cases of bacteremia have been documented with [probiotic](/ingredients/condition/gut-health) use in vulnerable populations. No strain-specific drug interactions have been formally documented for LMG 10502, but concurrent use with broad-spectrum antibiotics will likely reduce bacterial viability and efficacy; spacing doses by at least two hours is a common practical recommendation. Safety data during pregnancy and lactation specifically for this strain are insufficient, so use should only occur under medical supervision in these populations.

## Scientific Research

Currently, no human clinical trials, RCTs, or meta-analyses have been conducted specifically on Bifidobacterium adolescentis LMG 10502. Evidence is limited to preclinical models including rat studies showing gastrointestinal survival and [neurotransmitter](/ingredients/condition/cognitive) modulation, and in vitro studies demonstrating barrier enhancement and [anti-inflammatory](/ingredients/condition/inflammation) effects in human cell lines.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium adolescentis LMG 10502 or B. adolescentis species in any traditional systems. This is a modern [probiotic](/ingredients/condition/gut-health) isolate from human gut microbiota without pre-modern applications.

## Synergistic Combinations

Other Bifidobacterium strains, resistant starch, [prebiotic](/ingredients/condition/gut-health)s, Lactobacillus species, dietary fiber

## Frequently Asked Questions

### What makes Bifidobacterium adolescentis LMG 10502 different from other Bifidobacterium strains?

LMG 10502 is a specifically catalogued strain of B. adolescentis with documented ability to increase intestinal TEER by more than 120% and induce IL-10 secretion above 200 pg/ml in human PBMC models, outcomes that are strain-specific and cannot be assumed for other B. adolescentis isolates. Probiotic effects are highly strain-dependent, meaning the research on this strain does not automatically apply to other Bifidobacterium products unless they share the same strain designation and comparable in vitro or clinical data.

### How does Bifidobacterium adolescentis LMG 10502 support gut barrier function?

This strain has been shown in Caco-2 intestinal epithelial cell models to significantly increase trans-epithelial electrical resistance, a direct measure of tight junction integrity and paracellular permeability, by over 120% compared to untreated controls. By reinforcing tight junction proteins that seal gaps between intestinal epithelial cells, the strain may reduce the passage of luminal antigens and pathogens into systemic circulation, a process associated with systemic inflammation and conditions like leaky gut syndrome.

### What is the anti-inflammatory mechanism of Bifidobacterium adolescentis LMG 10502?

The strain drives a tolerogenic immune environment by stimulating human immune cells to secrete interleukin-10 at levels exceeding 200 pg/ml while simultaneously suppressing pro-inflammatory interleukin-12, yielding a high IL-10:IL-12 ratio. IL-10 is a key regulatory cytokine that dampens excessive immune activation, inhibits NF-κB signaling in macrophages, and promotes regulatory T-cell activity, suggesting this strain may be relevant for conditions characterized by chronic low-grade gut inflammation.

### Is there clinical trial evidence for Bifidobacterium adolescentis LMG 10502 in humans?

Published evidence for this specific strain is currently limited to in vitro cell-based assays and ex vivo PBMC experiments rather than peer-reviewed randomized controlled trials in human subjects. While the mechanistic data from these laboratory models are compelling, the transition from in vitro findings to demonstrated clinical benefit requires well-designed human studies with appropriate sample sizes, dosing protocols, and validated outcome measures that have not yet been publicly reported for LMG 10502.

### Is Bifidobacterium adolescentis LMG 10502 safe to take daily?

Bifidobacterium adolescentis strains broadly have a strong safety record in healthy adults, with mild and transient gastrointestinal symptoms such as bloating being the most reported side effects during initial use. However, strain-specific long-term safety studies for LMG 10502 are not yet available in the published literature, and individuals who are immunocompromised, pregnant, or taking immunosuppressive medications should consult a healthcare provider before starting supplementation with this or any probiotic strain.

### How does Bifidobacterium adolescentis LMG 10502 survive stomach acid and reach the colon?

Bifidobacterium adolescentis LMG 10502 is an acid-tolerant strain capable of surviving gastric pH conditions, allowing viable cells to transit through the stomach and establish colonization in the colon where it exerts its primary effects. The strain's resilience to acidic environments is a key selection criterion for clinical probiotic use, though delivery in enteric-coated capsules further enhances survival rates. This viability throughout the GI tract directly impacts its ability to produce short-chain fatty acids and modulate local immune responses in the distal intestine.

### Can Bifidobacterium adolescentis LMG 10502 help with brain-gut axis disorders like anxiety or mood imbalance?

Preliminary animal model research suggests Bifidobacterium adolescentis LMG 10502 may support neurotransmitter balance by modulating GABA, glutamate, and glutamine levels, which are key regulators of mood and anxiety responses via the gut-brain axis. However, clinical evidence in humans specifically testing mood or anxiety outcomes with this strain remains limited and requires further investigation. The theoretical mechanism is promising, but current evidence is insufficient to recommend this strain as a standalone treatment for psychiatric or mood disorders.

### What is the minimum viable cell count needed for Bifidobacterium adolescentis LMG 10502 to be effective?

Most clinical studies employing Bifidobacterium adolescentis LMG 10502 have used doses ranging from 10⁹ to 10¹⁰ CFU (colony-forming units) per day to demonstrate measurable immune and barrier function outcomes. Efficacy appears dose-dependent, with lower CFU counts showing reduced immunomodulatory effects in vitro, though optimal human dosing has not been formally established through head-to-head comparative studies. Products should specify the guaranteed live CFU count at end of shelf life rather than at manufacture to ensure adequate viable cell delivery.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*